|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 456.69 USD | -0.90% |
|
-8.08% | +0.73% |
Evolution of the Average Target: Vertex Pharmaceuticals Incorporated
Evolution of the Target Price: Vertex Pharmaceuticals Incorporated
Changes in Analyst Recommendations: Vertex Pharmaceuticals Incorporated
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +17.27% | |||||
| +22.62% | |||||
| -2.14% | |||||
| +8.15% | |||||
| +5.73% | |||||
| -4.52% | |||||
| +13.12% | |||||
| +9.87% | |||||
| -5.28% | |||||
| +8.8% | |||||
| Average | +7.36% | |||||
| Weighted average by Cap. | +8.89% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BMO Capital | |
| Daiwa Securities | |
| HC Wainwright | |
| Rothschild & Co Redburn | |
| Canaccord Genuity | |
| Barclays | |
| RBC Capital Markets | |
| Bernstein | |
| Stifel Nicolaus | |
| Scotiabank | |
| Cantor Fitzgerald | |
| Oppenheimer | |
| UBS | |
| Evercore ISI | |
| Goldman Sachs | |
| Wolfe Research | |
| Leerink Partners | |
| Wells Fargo Securities | |
| Morgan Stanley | |
| JPMorgan Chase | |
| Citigroup | |
| DBS Bank | |
| Argus | |
| Guggenheim | |
| Truist Securities | |
| Jefferies & Co. | |
| Redburn Atlantic | |
| Baird | |
| Piper Sandler | |
| Maxim | |
| BofA Securities | |
| TD Cowen | |
| SVB Securities LLC | |
| Cowen | |
| SVB Leerink | |
| Raymond James | |
| Credit Suisse |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VRTX Stock
- Consensus Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition